New York State Medicaid To Cover NeuroStar® Transcranial Magnetic Stimulation Therapy For Adults With Major Depressive Disorder (MDD)

Neuronetics, Inc., the maker of NeuroStar® Advanced Therapy, today announced that New York State Medicaid will begin covering transcranial magnetic stimulation (TMS) therapy for adults with major depressive disorder (MDD). Coverage will begin October 1, 2025, for fee-for-service Medicaid members and November 1, 2025, for Medicaid Managed Care enrollees.

This policy change expands access to nearly 1 million fee-for-service Medicaid members and more than 4.4 million individuals enrolled in Medicaid Managed Care Organizations across New York State.

“This decision by New York State Medicaid reflects the growing recognition of TMS as an evidence-based, life-changing treatment for patients with depression. We commend the state for making TMS more accessible to patients who need it most, and we remain committed to working alongside providers and policymakers to expand access nationwide,” said Keith J. Sullivan, President and CEO of Neuronetics, Inc. 

MDD affects an estimated 21 million adults in the U.S., with 6.4 million patients unable to tolerate or find adequate relief from antidepressant medications. NeuroStar Advanced Therapy offers a non-drug, non-invasive option, delivering targeted magnetic pulses to stimulate mood-regulating neurons in the brain. Data from the NeuroStar Outcomes Database shows that patients may achieve up to an 83% response rate and 62% remission rate with TMS.

Neuronetics is the only TMS company with a dedicated health policy team, actively working with providers and payors to drive policy updates that expand coverage and improve patient access to innovative neurohealth treatments.